ライフサイエンスコーパス: PPSV23

1 PPSV23 uptake varies substantially by age and indication

2 ompared to mock immunization (PPSV23 = 9.19, PPSV23/PLY = 10.45, PLY = 8.71, Mock = 16.83; P = 0.0467

3 h pneumolysin toxoid (psiPLY), Pneumovax 23 (PPSV23; Merck, Whitehouse Station, NJ), or phosphate-buf

4 cal polysaccharide vaccine (Pneumovax(R) 23; PPSV23) or PLY protects against pneumococcal endophthalm

5 Adding PPSV23 at age 75 years to PCV13 at ages 50 and 65 years

6 R range, 3.00-6.97), and little change after PPSV23 (GMFR range, 0.86-1.12).

7 Vitreous of PLY (2.88 MPO untis/mL) and PPSV23/PLY (2.17) passively immunized rabbits had less M

8 eading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (cellulitis)

9 t pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for asplenic i

10 cted corneas were higher for the psiPLY- and PPSV23-immunized rabbits after infection with WU2, when

11 previous observational studies and to assess PPSV23 vaccine effectiveness in preventing IPD and the m

12 ealth Interview Survey, the authors assessed PPSV23 uptake in people with established and new indicat

13 In these cases, PPSV23 as currently recommended was favored.

14 lin G (IgG) and functional antibody than did PPSV23 1 month after vaccination.

15 s 18-64 years of age (18.6%) had established PPSV23 indications; adding asthma and smoking to the lis

16 Disease Control and Prevention criteria for PPSV23 administration, almost 50% of individuals had nev

17 Vaccine effectiveness for PPSV23 was assessed using multivariable conditional logi

18 % of people with established indications for PPSV23 and 17.4% of people with any indication (those pr

19 rette smoking to the list of indications for PPSV23 vaccination.

20 administration of PCV13 as a substitute for PPSV23 in current recommendations (ie, vaccination at ag

21 ions (PLY = 31.34% loss of retinal function, PPSV23/PLY = 27.44%) helped to significantly preserve re

22 ical severity compared to mock immunization (PPSV23 = 9.19, PPSV23/PLY = 10.45, PLY = 8.71, Mock = 16

23 had previously received 1 or >/= 2 doses of PPSV23.

24 al disease, but the lack of effectiveness of PPSV23 in protecting against all-cause HTP should be con

25 with antiserum to PLY, PPSV23, a mixture of PPSV23/PLY, or PBS (mock).

26 tered the combination immunization (5.29) or PPSV23 (5.29) with vancomycin treatment compared to cont

27 V13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (cellulitis).

28 e passively immunized with antiserum to PLY, PPSV23, a mixture of PPSV23/PLY, or PBS (mock).

29 ividuals with beta-thalassemia, but previous PPSV23s affect the memory B-cell response in a dose- and

30 responses in HIV-infected adults with prior PPSV23 vaccination and CD4 cell counts >/= 200 cells/mm(

31 te to severe COPD were randomized to receive PPSV23 (n = 90) or PCV7 (1.0 mL; n = 91).

32 tors independently associated with receiving PPSV23, they used multivariable logistic regression and

33 ost-effective than the currently recommended PPSV23 strategy.

34 a greater functional antibody response than PPSV23 in patients with COPD that persists for 2 years a

35 The PPSV23 vaccine is effective against the most severe inva

36 Relative to PPSV23, PCV7 induced greater OPK at both 1 and 2 years f

37 -valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later.

38 -valent pneumococcal polysaccharide vaccine (PPSV23) among US adults is unclear.

39 -valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent PCV within specified geographic an

40 -valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4 cell counts >/= 200 cells/mm(3) and

41 -valent pneumococcal polysaccharide vaccine (PPSV23) for nonelderly adults with certain medical condi

42 -valent pneumococcal polysaccharide vaccine (PPSV23) for preventing all-cause pneumonia still undeter

43 -valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healt

44 insurance were independently associated with PPSV23 receipt.

45 PCV13 vaccination was favored compared with PPSV23, but the analysis was sensitive to assumptions ab

46 </= 0.0010), whereas rabbits immunized with PPSV23 and Freund's adjuvant failed to show differences

47 ntisera from rabbits actively immunized with PPSV23 and Freund's adjuvant were nonopsonizing.

48 nized with PBS and Freund's adjuvant or with PPSV23 and Freund's adjuvant at 48 hours after infection